DE60013811D1 - Intravenösen verabreichung von valproat zur behandlung von migränekopfschmerzen - Google Patents

Intravenösen verabreichung von valproat zur behandlung von migränekopfschmerzen

Info

Publication number
DE60013811D1
DE60013811D1 DE60013811T DE60013811T DE60013811D1 DE 60013811 D1 DE60013811 D1 DE 60013811D1 DE 60013811 T DE60013811 T DE 60013811T DE 60013811 T DE60013811 T DE 60013811T DE 60013811 D1 DE60013811 D1 DE 60013811D1
Authority
DE
Germany
Prior art keywords
treatment
intravenous administration
valproat
migraine headaches
migraine headache
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60013811T
Other languages
English (en)
Other versions
DE60013811T2 (de
Inventor
Keith R Edwards
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE60013811D1 publication Critical patent/DE60013811D1/de
Application granted granted Critical
Publication of DE60013811T2 publication Critical patent/DE60013811T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60013811T 1999-05-04 2000-05-04 Intravenösen verabreichung von valproat zur behandlung von migränekopfschmerzen Expired - Fee Related DE60013811T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13241699P 1999-05-04 1999-05-04
US132416P 1999-05-04
PCT/US2000/012317 WO2000066109A2 (en) 1999-05-04 2000-05-04 Intravenous valproate for acute treatment of migraine headache

Publications (2)

Publication Number Publication Date
DE60013811D1 true DE60013811D1 (de) 2004-10-21
DE60013811T2 DE60013811T2 (de) 2005-11-17

Family

ID=22453956

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60013811T Expired - Fee Related DE60013811T2 (de) 1999-05-04 2000-05-04 Intravenösen verabreichung von valproat zur behandlung von migränekopfschmerzen

Country Status (10)

Country Link
US (2) US7141247B2 (de)
EP (1) EP1181012B1 (de)
AT (1) ATE275950T1 (de)
AU (1) AU4703500A (de)
CA (1) CA2372806A1 (de)
DE (1) DE60013811T2 (de)
DK (1) DK1181012T3 (de)
ES (1) ES2228521T3 (de)
PT (1) PT1181012E (de)
WO (1) WO2000066109A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2228521T3 (es) 1999-05-04 2005-04-16 Keith R. Edwards Valproato intravenoso para el tratamiento agudo de la jaqueca.
US20050159985A1 (en) * 2003-11-21 2005-07-21 Bertram Carl T. System and method of stratifying intervention groups and comparison groups based on disease severity index scores and ranges
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
JP2008545650A (ja) 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
EA200870556A1 (ru) 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
NZ590682A (en) 2008-06-23 2012-09-28 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432176A (en) * 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
US5102913A (en) 1991-07-01 1992-04-07 Halikas James A Treatment for cocaine use employing valproic acid
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
KR20010071572A (ko) * 1998-06-22 2001-07-28 아메리칸 바이오지네틱 사이언스, 인코포레이티스 발프로산 유사체를 편두통 및 기분 장애의 치료 및 예방에사용하는 용도
ES2228521T3 (es) 1999-05-04 2005-04-16 Keith R. Edwards Valproato intravenoso para el tratamiento agudo de la jaqueca.

Also Published As

Publication number Publication date
WO2000066109A3 (en) 2001-02-15
US7163689B2 (en) 2007-01-16
EP1181012B1 (de) 2004-09-15
AU4703500A (en) 2000-11-17
CA2372806A1 (en) 2000-11-09
ES2228521T3 (es) 2005-04-16
WO2000066109A2 (en) 2000-11-09
PT1181012E (pt) 2005-02-28
EP1181012A2 (de) 2002-02-27
DE60013811T2 (de) 2005-11-17
ATE275950T1 (de) 2004-10-15
US20050245611A1 (en) 2005-11-03
US7141247B2 (en) 2006-11-28
US20020156131A1 (en) 2002-10-24
DK1181012T3 (da) 2005-01-24

Similar Documents

Publication Publication Date Title
DE60013811D1 (de) Intravenösen verabreichung von valproat zur behandlung von migränekopfschmerzen
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
AU4332302A (en) Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
FI962022A0 (fi) 5,6-dihydropyronijohdannaiset proteaasi-inhibiittoreina ja antiviraalisina aineina
EP0727994A4 (de) Antipyretische und analgetische verfahren und zusammensetzungen, die optisch reines r-etodolac enthalten
HUP0105281A2 (hu) Rákellenes hatású benzaldehidszármazékok és gyógyászati alkalmazásuk
NO20022920D0 (no) Nye forbindelser
DE69430671D1 (de) 5,6-dihydropyron derivate als protease inhibitoren und antivirusmitteln
MY139368A (en) Novel cyclohexyl sulphones
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
DE60026883D1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
ATE81462T1 (de) Glykosaminoglykan zur behandlung von diabetischer mikroangiopathie.
DE69924979D1 (de) Behandlung von chronischen schmerzen
ES8504109A1 (es) Procedimiento de producir compuestos para el tratamiento de la hipertension
ATE149840T1 (de) Behandlung von leberkrebs
DE60024408D1 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
DE60129599D1 (de) Faktor xiii in kombination mit faktor ix zur behandlung von hämophilie b
NO981489L (no) Blandinger av melatonin og analgetika samt anvendelser derav
UA40393A (uk) Спосіб лікування хронічного обструктивного бронхіту
DE69927985D1 (de) Verwendung von misoprostol oder/und misoprostol saüre zur herstellung eines arzneimittels zur behandlung weiblicher sexualer störung
UA43117A (uk) Спосіб лікування запальних захворювань передміхурової залози
ES2148057A1 (es) Nuevo uso del diacepam como potenciador del efecto de los inhibidores pde 3

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee